Michael Weller
Impact in
- Genetics top 0.01%
- Glioma Diagnosis and Treatment
- Cancer Research top 0.01%
- Cancer, Hypoxia, and Metabolism
- MicroRNA in disease regulation
Papers in
- Genetics 519
- Glioma Diagnosis and Treatment 510
-
- Cell death mechanisms and regulation 91
- Co-authors
- Wolfgang Wick (206 shared papers)Roger Stupp (78 shared papers)Martin J. van den Bent (97 shared papers)Thierry Gorlia (69 shared papers)Warren Mason (24 shared papers)R.O. Mirimanoff (7 shared papers)J. Gregory Cairncross (7 shared papers)Robert C. Janzer (2 shared papers)
- Journals
- Neuro-Oncology (155 papers)Journal of Clinical Oncology (92 papers)Journal of Neuro-Oncology (42 papers)Acta Neuropathologica (34 papers)Neurology (29 papers)
- Partner nations
- GermanySwitzerlandUnited States
In The Last Decade
Michael Weller
1.2k papers receiving 91.9k citations
Michael Weller's Hit Papers
Peers
Comparison fields: 5 of 200
- Genetics 39.7k
- Cancer Research 14.1k
- Neurology 8.9k
- Oncology 14.1k
- Immunology 11.1k
Countries citing papers authored by Michael Weller
This map shows the geographic impact of Michael Weller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Weller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Weller more than expected).
Fields of papers citing papers by Michael Weller
This network shows the impact of papers produced by Michael Weller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Weller. The network helps show where Michael Weller may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Weller, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.3k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma Hit paper breakdown → | 2005 | 16720 |
| 2 | MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma Hit paper breakdown → | 2005 | 5578 |
| 3 | An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor Hit paper breakdown → | 2011 | 1509 |
| 4 | Current state of immunotherapy for glioblastoma Hit paper breakdown → | 2018 | 992 |
| 5 | Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma Hit paper breakdown → | 2020 | 992 |
| 6 | Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas Hit paper breakdown → | 2009 | 924 |
| 7 | Glioma Hit paper breakdown → | 2015 | 833 |
| 8 | Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial Hit paper breakdown → | 2012 | 819 |
| 9 | Long-term survival with glioblastoma multiforme Hit paper breakdown → | 2007 | 703 |
| 10 | Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity Hit paper breakdown → | 2008 | 691 |
| 11 | Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas Hit paper breakdown → | 2010 | 661 |
| 12 | Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo Hit paper breakdown → | 2002 | 643 |
| 13 | NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide Hit paper breakdown → | 2009 | 619 |
| 14 | MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Hit paper breakdown → | 2009 | 612 |
| 15 | Standards of care for treatment of recurrent glioblastoma—are we there yet? Hit paper breakdown → | 2012 | 604 |
| 16 | EANO guidelines for the diagnosis and treatment of meningiomas Hit paper breakdown → | 2016 | 600 |
| 17 | EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma Hit paper breakdown → | 2014 | 589 |
| 18 | cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” Hit paper breakdown → | 2018 | 581 |
| 19 | Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas Hit paper breakdown → | 2016 | 526 |
| 20 | Immunotherapy response assessment in neuro-oncology: a report of the RANO working group Hit paper breakdown → | 2015 | 510 |
About Michael Weller
Michael Weller is a scholar working on Genetics, Molecular Biology, Oncology, Pulmonary and Respiratory Medicine and Neurology, having authored 1.3k papers that have together received 94.1k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (510 papers), Brain Metastases and Treatment (163 papers), Cell death mechanisms and regulation (91 papers), CNS Lymphoma Diagnosis and Treatment (60 papers), Cancer, Hypoxia, and Metabolism (57 papers), Cell Adhesion Molecules Research (55 papers), Immunotherapy and Immune Responses (53 papers) and Radiomics and Machine Learning in Medical Imaging (51 papers). The work is most often cited by research in Genetics (39.7k citations), Cancer Research (14.1k citations), Neurology (8.9k citations), Oncology (14.1k citations) and Immunology (11.1k citations). Michael Weller has collaborated with scholars based in Germany, Switzerland and United States. Frequent co-authors include Wolfgang Wick, Roger Stupp, Martin J. van den Bent, Thierry Gorlia, Warren Mason, R.O. Mirimanoff, J. Gregory Cairncross, Robert C. Janzer, Guido Reifenberger and Alba A. Brandes. Their work appears in journals such as Neuro-Oncology, Journal of Clinical Oncology, Journal of Neuro-Oncology, Acta Neuropathologica and Neurology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.